Proactive Investors - Run By Investors For Investors

Cellmid director shows faith in life sciences company through on-market trades

Bruce Gordon has acquired two batches of shares recently with a total value of almost $13,300.
Australian currency
The company has lead programs in multiple disease indications

Cellmid Limited (ASX:CDY) non-executive director Bruce Gordon continues to demonstrate his confidence in the life sciences company through on-market share purchases.

Gordon has acquired a further 8,684 shares valued at almost $3,300 and now holds 110,000 shares in an indirect interest.

Last week’s acquisition follows a recent purchase of more than 26,000 shares valued at $10,000.

READ: Cellmid gains new substantial shareholder as director increases his interest to 6.4%

Other company directors have also been acquiring shares recently in a variety of ways, including on-market trades and participation in the recent share placement and share purchase plan.
US-based non-executive director Dennis Eck is a substantial shareholder with a 6.4% interest after acquiring a further batch of shares valued at $1 million.

Managing director and CEO Maria Halasz acquired shares valued at $100,000 while non-executive director Dr Martin Cross has made purchases valued at $50,400.

READ: Cellmid driving towards profitability with anti-ageing product range

Cellmid is an Australian life sciences accelerator with lead programs in multiple disease indications.

The company holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. 

Cellmid, through wholly-owned subsidiaries Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart and hair loss.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use